Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1984 May;25(5):563–565. doi: 10.1128/aac.25.5.563

Enhanced efficacy of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine in combination with beta-interferon against herpes simplex virus type 2 in mice.

E B Fraser-Smith, D A Eppstein, Y V Marsh, T R Matthews
PMCID: PMC185586  PMID: 6610387

Abstract

The acyclic nucleoside 9-(1,3-dihydroxy-2- propoxymethyl )guanine (DHPG) and natural mouse interferon beta ( MuIFN -beta) were evaluated for their efficacy alone and in combination against herpes simplex virus type 2 systemic infections in mice. Intraperitoneally infected animals were treated once a day with the drugs at various concentrations for 5 days starting 24 h after inoculation. DHPG was injected subcutaneously at doses of 0.7 to 6 mg/kg. MuIFN -beta was given intraperitoneally at doses ranging from 3 X 10(3) to 3 X 10(4) IU per mouse. For DHPG alone, the effective dose at which 50% of the mice survived (ED50) was greater than 6 mg/kg. However, when given in combination with an ineffective dose of MuIFN -beta (10(4) IU per mouse), the ED50 for DHPG was 0.8 mg/kg. In addition, at the highest dose tested, MuIFN -beta alone had no protective activity against herpes simplex virus type 2 (ED50, greater than 3 X 10(4) IU per mouse). However, when given in combination with a marginally effective dose of DHPG (2 mg/kg), the ED50 for MuIFN -beta was less than 3 X 10(3) IU per mouse. Calculation of the fractional protective dose index (less than 0.23 where values of less than or equal to 0.5 are considered synergistic) indicates an enhanced protective interaction by the combination of the two drugs. These results represent the first time that potentiation of the antiviral activity of an acyclic nucleoside by interferon has been demonstrated in animal studies.

Full text

PDF
565

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ashton W. T., Karkas J. D., Field A. K., Tolman R. L. Activation by thymidine kinase and potent antiherpetic activity of 2'-nor-2'-deoxyguanosine (2'NDG). Biochem Biophys Res Commun. 1982 Oct 29;108(4):1716–1721. doi: 10.1016/s0006-291x(82)80109-5. [DOI] [PubMed] [Google Scholar]
  2. Berenbaum M. C. Synergy, additivism and antagonism in immunosuppression. A critical review. Clin Exp Immunol. 1977 Apr;28(1):1–18. [PMC free article] [PubMed] [Google Scholar]
  3. Cheng Y. C., Huang E. S., Lin J. C., Mar E. C., Pagano J. S., Dutschman G. E., Grill S. P. Unique spectrum of activity of 9-[(1,3-dihydroxy-2-propoxy)methyl]-guanine against herpesviruses in vitro and its mode of action against herpes simplex virus type 1. Proc Natl Acad Sci U S A. 1983 May;80(9):2767–2770. doi: 10.1073/pnas.80.9.2767. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Field A. K., Davies M. E., DeWitt C., Perry H. C., Liou R., Germershausen J., Karkas J. D., Ashton W. T., Johnston D. B., Tolman R. L. 9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine: a selective inhibitor of herpes group virus replication. Proc Natl Acad Sci U S A. 1983 Jul;80(13):4139–4143. doi: 10.1073/pnas.80.13.4139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fraser-Smith E. B., Smee D. F., Matthews T. R. Efficacy of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine against primary and recrudescent genital herpes simplex virus type 2 infections in guinea pigs. Antimicrob Agents Chemother. 1983 Dec;24(6):883–887. doi: 10.1128/aac.24.6.883. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Janz C., Wigand R. Combined interaction of antiherpes substances and interferon beta on the multiplication of herpes simplex virus. Arch Virol. 1982;73(2):135–143. doi: 10.1007/BF01314722. [DOI] [PubMed] [Google Scholar]
  7. Kern E. R., Glasgow L. A. Evaluation of interferon and interferon inducers as antiviral agents: animal studies. Pharmacol Ther. 1981;13(1):1–38. doi: 10.1016/0163-7258(81)90065-6. [DOI] [PubMed] [Google Scholar]
  8. Kohl S. Stimulation of human natural killer cytotoxicity and protection of mice from infection due to herpes simplex virus by recombinant human leukocyte interferon. J Infect Dis. 1983 Mar;147(3):484–488. doi: 10.1093/infdis/147.3.484. [DOI] [PubMed] [Google Scholar]
  9. Levin M. J., Leary P. L. Inhibition of human herpesviruses by combination of acyclovir and human leukocyte interferon. Infect Immun. 1981 Jun;32(3):995–999. doi: 10.1128/iai.32.3.995-999.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Levin S. Interferon in acute viral infections. Eur J Pediatr. 1983 Mar;140(1):2–4. doi: 10.1007/BF00661894. [DOI] [PubMed] [Google Scholar]
  11. Martin J. C., Dvorak C. A., Smee D. F., Matthews T. R., Verheyden J. P. 9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine: a new potent and selective antiherpes agent. J Med Chem. 1983 May;26(5):759–761. doi: 10.1021/jm00359a023. [DOI] [PubMed] [Google Scholar]
  12. Olsen G. A., Kern E. R., Overall J. C., Jr Effect of treatment with exogenous interferon, polyriboinosinic-polyribocytidylic acid, or polyriboinosinic-polyribocytidylic acid-poly-L-lysine complex on Herpesvirus hominis infections in mice. J Infect Dis. 1978 Apr;137(4):428–436. doi: 10.1093/infdis/137.4.428. [DOI] [PubMed] [Google Scholar]
  13. Pazin G. J., Armstrong J. A., Lam M. T., Tarr G. C., Jannetta P. J., Ho M. Prevention of reactivated herpes simplex infection by human leukocyte interferon after operation on the trigeminal root. N Engl J Med. 1979 Aug 2;301(5):225–230. doi: 10.1056/NEJM197908023010501. [DOI] [PubMed] [Google Scholar]
  14. Quinot J. F., Delatte P., Flye Sainte Marie F., Richard C. Gangrène gazeuse à Aeromonas hydrophila. Un piège thérapeutique. Nouv Presse Med. 1982 Sep 25;11(37):2783–2784. [PubMed] [Google Scholar]
  15. Rollinson E. A., White G. Relative activities of acyclovir and BW759 against Aujeszky's disease and equine rhinopneumonitis viruses. Antimicrob Agents Chemother. 1983 Aug;24(2):221–226. doi: 10.1128/aac.24.2.221. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Rose R. M., Crumpacker C., Waner J. L., Brain J. D. Treatment of murine cytomegalovirus pneumonia with acyclovir and interferon. Am Rev Respir Dis. 1983 Feb;127(2):198–203. doi: 10.1164/arrd.1983.127.2.198. [DOI] [PubMed] [Google Scholar]
  17. Smee D. F., Martin J. C., Verheyden J. P., Matthews T. R. Anti-herpesvirus activity of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine. Antimicrob Agents Chemother. 1983 May;23(5):676–682. doi: 10.1128/aac.23.5.676. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Smith K. O., Galloway K. S., Kennell W. L., Ogilvie K. K., Radatus B. K. A new nucleoside analog, 9-[[2-hydroxy-1-(hydroxymethyl)ethoxyl]methyl]guanine, highly active in vitro against herpes simplex virus types 1 and 2. Antimicrob Agents Chemother. 1982 Jul;22(1):55–61. doi: 10.1128/aac.22.1.55. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Stanwick T. L., Schinazi R. F., Campbell D. E., Nahmias A. J. Combined antiviral effect of interferon and acyclovir on herpes simplex virus types 1 and 2. Antimicrob Agents Chemother. 1981 Apr;19(4):672–674. doi: 10.1128/aac.19.4.672. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Wade J. C., McGuffin R. W., Springmeyer S. C., Newton B., Singer J. W., Meyers J. D. Treatment of cytomegaloviral pneumonia with high-dose acyclovir and human leukocyte interferon. J Infect Dis. 1983 Sep;148(3):557–562. doi: 10.1093/infdis/148.3.557. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES